Kan Yonemori
- Oncology top 0.5%
- Pulmonary and Respiratory Medicine top 1%
- Molecular Biology top 5%
- Radiology, Nuclear Medicine and Imaging top 1%
- Cancer Research top 2%
- Co-authors
- Yasuhiro FujiwaraKenji TamuraChikako ShimizuMasashi AndoMayu YunokawaNoriyuki KatsumataMakoto KodairaTatsunori Shimoi
- Topics
- HER2/EGFR in Cancer Research (70 papers)Sarcoma Diagnosis and Treatment (59 papers)Cancer Treatment and Pharmacology (45 papers)
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Kan Yonemori
372 papers receiving 6.0k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Oncology 3.8k
- Pulmonary and Respiratory Medicine 1.9k
- Molecular Biology 1.4k
- Radiology, Nuclear Medicine and Imaging 1.0k
- Cancer Research 898
Countries citing papers authored by Kan Yonemori
This map shows the geographic impact of Kan Yonemori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kan Yonemori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kan Yonemori more than expected).
Fields of papers citing papers by Kan Yonemori
This network shows the impact of papers produced by Kan Yonemori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kan Yonemori. The network helps show where Kan Yonemori may publish in the future.
Co-authorship network of co-authors of Kan Yonemori
This figure shows the co-authorship network connecting the top 25 collaborators of Kan Yonemori. A scholar is included among the top collaborators of Kan Yonemori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kan Yonemori. Kan Yonemori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 8 | |
| 3 | 5 | |
| 4 | 1 | |
| 5 | Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).breakdown → | 52 |
| 6 | 1 | |
| 7 | 2 | |
| 8 | 1 | |
| 9 | 1 | |
| 10 | 25 | |
| 11 | 9 | |
| 12 | 2 | |
| 13 | 2 | |
| 14 | 4 | |
| 15 | 1 | |
| 16 | 5 | |
| 17 | 5 | |
| 18 | 13 | |
| 19 | 8 | |
| 20 | 24 |
About Kan Yonemori
Kan Yonemori is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 392 papers that have together received 6.2k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (70 papers), Sarcoma Diagnosis and Treatment (59 papers) and Cancer Treatment and Pharmacology (45 papers). The work is most often cited by research in Oncology (3.8k citations), Cancer Research (898 citations) and Pulmonary and Respiratory Medicine (1.9k citations). Kan Yonemori has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Yasuhiro Fujiwara, Kenji Tamura, Chikako Shimizu, Masashi Ando, Mayu Yunokawa, Noriyuki Katsumata, Makoto Kodaira, Tatsunori Shimoi, Akihiko Shimomura and Takayuki Kinoshita. Their work appears in journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.